Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics

Archives of Internal Medicine

Volumn 163, Issue 1, 2003, Pages 76-80

  Reyes, Michele ^a   Shaik, Nazerah S ^a   Graber, Judith M ^a   Nisenbaum, Rosane ^a   Wetherall, Neal T ^a   Fukuda, Keiji ^a   Reeves, William C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENCE; LEUKOCYTE COUNT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; UNITED STATES; VIRUS ISOLATION; VIRUS PLAQUE;

EID: 0037434062     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.1.76     Document Type: Article

References (30)

1. Corey L, Handsfield HH. Genital herpes and public health: addressing a global problem. JAMA. 2000;283:791-794.
2. Becker TM, Blount JH, Guinan ME. Genital herpes infections in private practice in the United States, 1966 to 1981. JAMA. 1985;253:1601-1603.
3. National Center for HIV, STD, and TB Prevention. Sexually Transmitted Disease Surveillance, 1996. Atlanta, Ga: Centers for Disease Control and Prevention; September 1997.
4. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med. 1997;337:1105-1111.
5. Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med. 2000;342:844-850.
6. Corey L, Langenberg AGM, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: 2 randomized controlled trials. JAMA. 1999;282:331-340.
7. Wald A, Zeh J, Barnum G, Davis LG, Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med. 1996;124:8-15.
8. Centers for Disease Control and Prevention. Guidelines for treatment of sexually transmitted diseases. MMWR Recomm Rep. 1998;47(RR-1):20-25.
9. Whitley RJ, Gnann JW Jr. Acyclovir: a decade later [published corrections appear in N Engl J Med. 1993;328:671 and N Engl J Med. 1997;337:1703]. N Engl J Med. 1992;327:782-789.
10. Lederberg J, Shope RE, Oaks SC, eds. Emerging Infections: Microbial Threats to Health in the United States. Washington, DC: National Academy Press; 1992.
11. Sibrack CD, Gutman LT, Wilfert CM, et al. Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child. J Infect Dis. 1982; 146:673-682.
12. Crumpacker CS, Schnipper LE, Marlow SI, Kowalsky PN, Hershey BJ, Levin MJ. Resistance to antiviral drugs in herpes simplexvirus isolated from a patient treated with acyclovir. N Engl J Med. 1982;306:343-346.
13. Pillay D. Emergence and control of resistance to antiviral drugs in resistance in herpes viruses, hepatitis B virus, and HIV. Commun Dis Public Health. 1998;1:5-13.
14. Christophers J, Clayton J, Craske J, et al. Survey of resistance of herpes simplex virus to acyclovir in northwest England. Antimicrob Agents Chemother. 1998; 42:868-872.
15. Erlich KS, Mills J, Chatis P, et al. Acyclovir-resistant HSV infections in patients with AIDS. N Engl J Med. 1989;320:293-296.
16. Epstein JB, Scully C. Herpes simplexvirus in immunocompromised patients: growing evidence of drug resistance. Oral Surg Oral Med Oral Pathol. 1991;72:47-50.
17. Englund JA, Zimmerman ME, Swierkosz EM, et al. Herpes simplex virus resistant to acyclovir: a study in a tertiary care center. Ann Intern Med. 1990;112:416-422.
18. Christophers J, Sutton RN. Characterization of acyclovir-resistant and sensitive clinical herpes simplex virus isolates from an immunocompromised patient. J Antimicrob Chemother, 1987;20:389-398.
19. Safrin S, Crumpacker CS, Chatis PA, et al. Treatment of acyclovir-resistant mucocutaneous herpes simplex infection in patients with the acquired immunodeficiency syndrome: a randomized multicenter study of foscarnet vs vidarabine. N Engl J Med. 1991;325:551-555.
20. Collins P, Appleyard G, Oliver NM. Sensitivity of herpes virus isolates from acyclovir clinical trials. Am J Med. 1982;73:380-382.
21. Safrin S, Elbeik T, Phan L, et al. Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 1994;38:1246-1250.
22. Pottage JCJ, Kessler HA. Herpes simplex virus resistance to acyclovir: clinical relevance. Infect Agents Dis. 1995;4:115-124.
23. Field HJ, Darby G. Pathogenicity in mice of strains of herpes simplexvirus which are resistant to acyclovir in vitro and in vivo. Antimicrob Agents Chemother. 1980;17:209-216.
24. Schnipper LE, Crumpacker CS. Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci. Proc Natl Acad Sci U S A. 1980;77:2270-2273.
25. Fife KH, Crumpacker CS, Mertz GJ, Hill EL, Boone GS. Recurrence and resistance patterns of herpes simplex virus following cessation of ≥6 years of chronic suppression with acyclovir. J Infect Dis. 1994;169:1338-1341.
26. McLaren C, Corey L, Dekket C, Barry DW. In vitro sensitivity to acyclovir in genital herpes simplex viruses from acyclovir-treated patients. J Infect Dis. 1983; 148:868-875.
27. Al-Hasani AM, Barton IG, Al-Omer LS, Kinghorn GR, Potter CW. Susceptibility of HSV strains from patients with genital herpes treated with various formulations of acyclovir. J Antimicrob Chemother. 1986;18(suppl B):113-119.
28. Sacks SL, Wanklin RJ, Reece DE, Hicks KA, Tyler KL, Coen DM. Progressive esophagitis from acyclovir-resistant herpes simplex. Ann Intern Med. 1989;111:893-899.
29. Blower SM, Porco TC, Darby G. Predicting and preventing the emergence of antiviral drug resistance in HSV-2. Nature Med. 1998;4:673-678.
30. White PJ, Garnett GP. Use of antiviral treatment and prophylaxis is unlikely to have a major impact on the prevalence of herpes simplex virus type 2. Sex Transm Infect. 1999;75:49-54.